Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163137
Status:
COMPLETED
Last Update Posted:
2011-08-12
First Post:
2005-09-09
Brief Title:
Comparison of Raloxifene and Lasofoxifene - A Randomized Blinded Study of These Drugs and Placebo on Bone Loss
Sponsor:
Ligand Pharmaceuticals
Organization:
Ligand Pharmaceuticals
Study Overview
Official Title:
Double-Blind Placebo-Controlled Trial Of The Safety Toleration and Efficacy Of Lasofoxifene 025 MgD and Raloxifene 60MgD For The Prevention Of Bone Loss In Postmenopausal Women
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CORAL
Brief Summary:
To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mgday use and 2 years of placebo use on bone mineral density BMD of the lumbar spine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None